Tranzyme Pharma and Norgine Complete Enrollment in ULISES 008, the Second of Two Phase 3 Pivotal Trials of Ulimorelin

Published: Feb 28, 2012

RESEARCH TRIANGLE PARK, N.C. and AMSTERDAM, the Netherlands, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 008, the second of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing abdominal surgery. Enrollment in ULISES 007, the first Phase 3 pivotal trial, was completed in December 2011. There are an estimated 1 million patients in the U.S. at high risk each year for delayed GI recovery after surgery, including approximately 340,000 bowel resection surgeries.

Back to news